RNXT earnings: next report 2026-08-13, real EPS beat/miss history, analyst consensus Buy, P/E -2.58. Updated 2026-07-23.
RenovoRx (RNXT) Research Hub
RenovoRx (RNXT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.76 USD (-12.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.58, market cap 0.03B. This hub links to the full technical, earnings and options research available for RNXT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.76 USD (-12.00%) |
| 52-week range | 0.84 USD – 2.54 USD |
| Trend regime | Range |
| 14-day RSI | 65.8 (Bullish) |
| Trailing P/E | -2.58 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-13 |
Available research for RNXT
Covered Call on RNXT: how it works, illustrative setup around the real 1.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RNXT: how it works, illustrative setup around the real 1.76 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RNXT: how it works, illustrative setup around the real 1.76 USD price, max profit/loss, breakeven and when to use it. Educational.
RNXT technical analysis: range, last 1.76 USD, RSI 65.8, 52w range 0.84 USD–2.54 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is RNXT in?
RenovoRx (RNXT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RNXT in an uptrend or downtrend?
As of 2026-09-11, RNXT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RNXT's trailing P/E ratio?
RNXT's trailing P/E is -2.58, with a market cap of 0.03B. See the earnings research page for full valuation detail.
When does RNXT next report earnings?
RNXT is next scheduled to report earnings on 2026-08-13, with a consensus EPS estimate of -0.08 USD.